News
Peptide research news
Recent reporting from peer-reviewed journals, clinical trial readouts, and reputable outlets. Curated by Perplexity, sources cited.
New research: Selank preclinical findings
A research roundup describes 2026 preclinical findings involving Selank, including rat studies reporting partial correction of stress-related cytokine changes and reductions in markers associated with neuronal cell death.
Modified resin-cleavage chemistry improves peptide synthesis yields
Researchers reported that adding small amounts of concentrated hydrochloric acid to a standard TFA cleavage cocktail improved peptide release from Rink Amide resin, with reported yield gains of 9% to 52%.
A New, Stronger GLP-1 Is Currently in Clinical Trials. Here's What Researchers Want You to Know
The report explains how retatrutide differs from semaglutide and tirzepatide: it targets GLP-1, GIP, and glucagon receptors. It remains investigational and is being evaluated in Phase 3 studies.
‘For Research Use Only’ Peptides: Why the FDA Treats Them as Drugs
The article reviews FDA enforcement involving tesamorelin and PT-141 and reports Australian health concerns involving unapproved products that may contain BPC-157, TB-500, and CJC-1295.
Could Retatrutide Break a GLP-1 Weight-Loss Plateau?
An analysis discusses whether investigational triple agonist retatrutide could help address weight-loss plateaus. The cited TRIUMPH-1 results showed average weight loss of 28.3% at 80 weeks at the highest studied dose; retatrutide is not FDA-approved.
Novo's CagriSema shows 25% weight loss in women
Novo Nordisk reported analyses linking CagriSema with reduced abdominal fat, measured by waist circumference, among women across menopause stages.
Rusfertide improves hematocrit control in Phase 3 VERIFY trial
The Phase 3 VERIFY trial reportedly found that weekly rusfertide produced a clinical response in 77% of phlebotomy-dependent adults with polycythemia vera versus 33% with placebo, alongside fewer phlebotomies and improved fatigue scores. The result was attributed to a Journal of Clinical Oncology publication.
Retatrutide obesity trial reportedly shows substantial weight loss
The report claims a Phase 3 retatrutide obesity trial published in the New England Journal of Medicine found 28.3% mean weight loss at 80 weeks and 30.3% at 104 weeks. The result should be independently verified against the journal record before publication.
Could retatrutide break a GLP-1 weight-loss plateau?
Coverage of the TRIUMPH-1 trial reported average weight loss of 28.3% at 80 weeks with the highest studied retatrutide dose. The article emphasized that retatrutide remains investigational and is not FDA-approved.